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Rational Choices for Allocating 
Antiretrovirals in Africa: Treatment 
Equity, Epidemiological Efﬁ  ciency, 
and Feasibility
David P. Wilson, Sally M. Blower
We agree with the thesis of Rosen et al. [1] that, despite 
initiatives such as the World Health Organization’s “3 by 
5” program, rationing of HIV/AIDS antiretroviral therapy 
(ART) will be necessary in the majority of African countries. 
Difﬁ  cult choices will need to be made, and choices will be 
constrained due to the limited health infrastructure and lack 
of qualiﬁ  ed health personnel in many African countries. 
Rosen et al. outlined a number of useful rationing systems 
and selection criteria [1]. 
However, some of the strategies they suggest are 
unfortunately not feasible in practice. For example, targeting 
behavioral core groups (high-risk groups, e.g., female sex 
workers) may well be impossible as it is not always possible 
to identify behavioral core groups. Furthermore, once the 
prevalence of HIV becomes extremely high in the general 
population (as it already is in many African countries), 
the concept of a behavioral core group will be relatively 
meaningless.
Previously, it has been shown, by using mathematical 
modeling, that targeting a virologic core group for treatment 
could be a very effective public health strategy for controlling 
herpes epidemics [2]. Only relatively few of the individuals 
infected with herpes simplex virus type 2 (HSV-2) are high viral 
shedders, and these individuals constitute the virologic core 
group. These individuals disproportionately contribute to the 
HSV-2 incidence rate. Thus, treating only the relatively few 
individuals who constitute the virologic core group has been 
shown to have a substantial effect on reducing the incidence 
of herpes [2]. Such a public health strategy for controlling 
herpes epidemics would be feasible, as it would be possible to 
identify the high viral shedders (i.e., the virologic core group) 
[2]. Such a strategy would also ensure that relatively few drugs 
would be needed to achieve epidemic control. 
We suggest that when considering how to ration 
antiretrovirals among individuals with HIV in Africa, instead 
of targeting behavioral core groups, HIV virologic core groups 
should be targeted. Individuals with HIV who constitute 
the HIV virologic core group would be easy to identify 
simply by measuring viral load. The virologic core group 
will be composed of individuals with a high viral load. These 
individuals would not only be people in the late stage of 
disease, but would also include recently infected individuals, 
who have a high viral set point. Targeting the HIV virological 
core group would have several advantages: it would increase 
treatment equity (as these individuals have the greatest need 
for treatment), it would be epidemiologically efﬁ  cient, and it 
would also be feasible. Whereas targeting the HIV behavioral 
core group would decrease treatment equity, it may or may not 
be epidemiologically efﬁ  cient and would not be feasible. 
Treatment equity and epidemiological efﬁ  ciency are 
likely to have very different weights in each African society. 
Previously, we have shown, by using operational research 
methodology, that it is possible to use mathematics to decide 
how to achieve treatment equity [3]. Thus, it is possible to 
devise a mathematically ethical solution to decide how to 
allocate a scarce supply of antiretrovirals if the objective is to 
achieve treatment equity [3]. We have shown that treatment 
equity is only possible in some areas of South Africa if each of 
the available health-care facilities treat individuals with HIV in 
a large catchment area (radius of approximately 40–60 km2) 
[3]. Hence, in some African countries, it may be impossible 
to achieve treatment equity even if it is possible to achieve a 
rationing strategy that would ensure the maximum reduction 
of the epidemic. Therefore, government ofﬁ  cials and health 
policy experts in each African country will have to decide 
the relative weight that they wish to place on treatment 
equity versus epidemiological efﬁ  ciency when they decide 
how to ration their scarce supply of antiretrovirals. We also 
stress that when using mathematical models to evaluate any 
rationing strategy, single scenarios should not be used to 
make complex decisions. There is a large degree of variability 
in the parameters that deﬁ  ne each strategy and a great deal 
of heterogeneity in how a given strategy will be implemented. 
Accordingly, we recommend that time-dependent uncertainty 
boundaries should always be presented in any analysis when 
modeling is being used for health policy decision making [4]. 
In addition, detailed time-sensitivity analyses should also be 
presented so that it is possible to evaluate the robustness of 
the results [4].
Finally, we would like to stress the tremendous value in 
preferentially making ART available to mothers with HIV 
(especially women who are pregnant or breast-feeding), both 
to prevent vertical transmission and to act as a therapeutic 
intervention for the mother. Not only would this rationing 
strategy reduce the burden of orphan support, but the 
treatment regimen is relatively cheap and is extremely 
effective in reducing transmission to infants and increasing 
the life expectancy of the mother. Therefore, we strongly 
recommend that no pregnant woman with HIV be overlooked 
in the rationing of ART.  
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How to Take HIV Antiretroviral 
Medications on Time without a Watch 
in Rural Uganda
Marissa Maier, Mwebesa Bwana, Nneka Emenyonu, 
Larry Pepper, David R. Bangsberg
Castro has advocated that adherence to HIV antiretroviral 
therapy should be understood within a patient’s clinical and 
social context [1]. Over 90% of worldwide HIV infection 
occurs in resource-limited settings [2]. Some have suggested 
that individuals living in extreme poverty may have difﬁ  culties 
with adherence to medication [3], including Andrew 
Natisios, who said Africans “don’t know what Western time 
is” [4]. While recent reports suggest that adherence to HIV 
antiretroviral therapy in resource-limited settings may be 
as good as or better than resource-rich settings [5–7], the 
question remains: how do people take medications on time 
without a watch?
In rural western Uganda, there is, for example, a 40-year-
old man who is HIV-positive, has no education, and works 
as a farmer. He lives with his brother, sister-in-law, and three 
nieces in a three-room, mud-walled house without electricity. 
He owns a lantern, a bed, a sofa, a bike, and a radio, but 
does not own a watch. He was diagnosed with HIV in April 
2005 and started generic D4T/3TC/NVP (Triomune) four 
months after developing disseminated herpes zoster and 
Kaposi sarcoma with a CD4 count of 151. His adherence 
was measured with an electronic medication monitor that 
records a date-time stamp in ﬂ  ash memory each time the 
pill container is opened. Over the 89 days of monitored 
treatment, he had 98.9% adherence by electronic monitor 
and took 90% of prescribed doses within ten minutes of 7:20 
a.m. and within 17 minutes of 7:20 p.m. When asked how he 
knew when to take his dose, he said that he knows it is time to 
take his medications by “listening to Radio West’s ‘News and 
Announcements’ every morning and evening.” 
While population levels of adherence will likely drop as 
treatment access expands and people begin to experience 
toxicities of long-term therapy, he is an example of how 
patients can have precise, if not perfect, adherence with 
creative solutions in a resource-limited setting.  
Marissa Maier 
Nneka Emenyonu 
David R. Bangsberg (db@epi-center.ucsf.edu)
University of California San Francisco
San Francisco, California, United States of America
Mwebesa Bwana
Larry Pepper
Mbarara University of Science and Technology 
Mbarara, Uganda
References
1.  Castro A (2005) Adherence to antiretroviral therapy: Merging the clinical 
and social course of AIDS. PLoS Med 2: e338. DOI: 10.1371/journal.
pmed.0020338
2.  Russell S (2001 June 8) AIDS activists in uproar over ofﬁ  cial’s remarks on 
Africa. San Francisco Chronicle; Sect A: 5. Available: http:⁄⁄www.sfgate.
com/cgi-bin/article.cgi?f=/c/a/2001/06/08/MN164875.DTL. Accessed 7 
February 2006.
3.  Stevens W, Kaye S, Corrah T (2004) Antiretroviral therapy in Africa. BMJ 
328: 280–282.
4.  Joint United Nations Programme on HIV/AIDS [UNAIDS] (2004) Report 
on the global AIDS epidemic: Executive summary. Geneva: UNAIDS. 
Available: http:⁄⁄www.unaids.org/bangkok2004/GAR2004_html/
ExecSummary_en/ExecSumm_00_en.htm. Accessed 7 February 2006.
5.  Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, et al. 
(2004) Multiple validated measures of adherence indicate high levels of 
adherence to generic HIV antiretroviral therapy in a resource-limited 
setting. J Acquir Immune Deﬁ  c Syndr 36: 1100–1102.
March 2006  |  Volume 3  |  Issue 3  |  e160  |  e161
DOI: 10.1371/journal.pmed.0030161.g001
Electronic medication monitor adherence record of time of 
bottle openings for morning and evening doses
DOI: 10.1371/journal.pmed.0030161.g002
Patient with his radioPLoS Medicine  |  www.plosmedicine.org 0412
6.  Orrell C, Bangsberg D, Badri M, Wood R (2003) Adherence is not a barrier 
to delivery of HIV antiretroviral therapy in resource-poor countries. AIDS 
17: 1369–1375.
7.  Laurent C, Kouanfack C, Koulla-Shiro S, Nkoue N, Bourgeois A, et al. 
(2004) Effectiveness and safety of a generic ﬁ  xed-dose combination 
of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in 
Cameroon: Open-label multicentre trial. Lancet 364: 29–34.
Citation: Maier M, Bwana M, Emenyonu N, Pepper L, Bangsberg DR (2006) How to 
take HIV antiretroviral medications on time without a watch in rural Uganda. PLoS 
Med 3(3): e161.
Copyright: © 2006 Maier et al. This is an open-access article distributed under the 
terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author 
and source are credited.
Competing Interests: The authors have declared that no competing interests 
exist. All procedures were approved by the Mbarara University of Science and 
Technology Human Subjects Committee, University of California Human Subjects 
Committee, and the Ugandan National Council of Science and Technology. 
Funding was provided by NIMH 54907, NIAAA 15287, UCSF-GIVI Fogarty, and The 
Doris Duke Charitable Foundation.
DOI: 10.1371/journal.pmed.0030161
Clinical Trials Registration
Frank W. Rockhold, Ronald L. Krall 
We read with great interest the recent Policy Forum by 
Karmela Krleža-Jeri  in PLoS Medicine on clinical trial 
registration [1]. GlaxoSmithKline (GSK) is committed to 
enhancing the transparency of clinical trial information 
through protocol registration and through registration of the 
results of clinical trials.
We are, therefore, disappointed that the article suggests 
the pharmaceutical industry is reluctant to embrace greater 
transparency and disclosure. In September 2004, GSK 
became the ﬁ  rst company, and we believe the ﬁ  rst trial 
sponsor, to establish a publicly available, Internet-based 
clinical trial register to provide results from all GSK-
sponsored clinical trials of marketed medicines. The register 
currently has over 2,000 records, and there are now similar 
registers and databases across industry. Indeed, as Krleža-
Jeri  notes, in January 2005, industry made a commitment 
to disclose clinical trial information (summary protocol and 
results) on clinical trial registers and databases, which has 
been followed by a further position paper in September 2005. 
This latter position paper conﬁ  rms industry’s support for 
the agreement reached at the World Health Organization 
(WHO) Technical Consultation Meeting on Clinical Trials 
Registration Standards held on 25–27 April 2005. Moreover, 
industry has launched a clinical trial portal to enable and to 
facilitate access to clinical trial information.
The article focuses on the registration of clinical trial 
protocol information, and we agree that it is important to 
alert physicians and patients of the opportunity to participate 
in and to serve as a public record to ensure results are 
publicly disclosed. However, we are surprised that Krleža-Jeri  
makes little mention of results registration. It is registration 
of results (not summary protocol information) that helps to 
ensure that researchers, physicians, and others are aware of 
all the relevant information from clinical trials of medical 
interventions and can review the literature appropriately—it 
is this which can affect patient care.
With regard to registration of summary protocol 
information, we can appreciate that the discussion and 
debate around the WHO minimal dataset and the ﬁ  ve data 
elements may have given the impression that industry is 
not embracing the concept of transparency and disclosure. 
However, industry has made the point about competitively 
sensitive information for a very good reason—that disclosure 
of one or more of these ﬁ  ve data elements early in the process 
of drug development may undermine medicine development. 
The discovery and development of medicines is fundamental 
in the social contract that the pharmaceutical industry has 
with society, and undermining this contract is not in the 
interests of patients and society in general. Nonetheless, it 
is important to recognise that delay of one or more data 
elements will be by exception only. Industry will, whenever 
possible, disclose all 20 data elements in the WHO minimal 
dataset. GSK, for example, will only delay registration of one 
data element for some early phase (exploratory) trials, and 
that has to be approved by our Chief Medical Ofﬁ  cer, Ronald 
Krall. All GSK-sponsored trials that, to use the International 
Committee of Medical Journal Editors (ICMJE) terminology, 
are “clinically directive” will be registered with all 20 data 
elements. The GSK approach is fully aligned with the 
ICMJE policy. Therefore, we do not believe that an escrow 
mechanism or another elaborate mechanism is required or 
justiﬁ  ed for such a small number of data elements in such 
a small number of trials. We would, however, be concerned 
if in practice the frequency of delays was high. Therefore, 
a pragmatic way forward would be to review practice after 
12–18 months to assess the extent of the issue (if any). 
We hope these comments are helpful and constructive. We 
would be happy to discuss our views with the author in greater 
detail at any time if that would be helpful.  
Frank W. Rockhold (frank.w.rockhold@gsk.com)
Ronald L. Krall (ronald.l.krall@gsk.com)
GlaxoSmithKline 
King of Prussia, Pennsylvania, United States of America
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Author’s Reply
It is a great pleasure to read that GlaxoSmithKline (GSK) is 
committed to registering its trial protocols and results [1]. I 
am also happy to hear that GSK intends to disclose at least the 
20 items of the World Health Organization (WHO) minimal 
dataset, and does not believe there is a need for escrow. What 
a great example! 
However, GSK’s own registry is not what I would describe 
as an unbiased registry. It is a good and convenient tool to 
have—for GSK—but trials should be registered in a neutral, 
unbiased registry such as ClinicalsTrials.gov, the International 
Standard Randomized Controlled Trial Number (ISRCTN) 
Registry, or the Australian Clinical Trials Registry (ACTR). 
Such registration will be a great step forward, as previously 
GSK and many other companies have often provided 
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incomplete information to trial registries, when registering 
their trials. Following personal communication from D. Zarin 
at the time of the publication of my paper in PLoS Medicine 
[2], the National Institutes of Health (NIH) performed 
further analysis, and a paper was published in the New 
England Journal of Medicine [3]. This paper illustrates that even 
now—and despite medical journal editors’ statements, WHO 
Guidelines, as well as other pressures such as the Ottawa 
Statement—industry inputs into ClinicalTrials.gov, which is 
the most often used trial registry, although improved, still 
leave much to be desired.
I disagree with Rockhold–Krall’s statement regarding results 
versus protocol. Both are needed to ensure awareness of the 
relevant information for informed clinical decision making. 
I limited myself to protocol registration, because this is the 
ﬁ  rst step that we need to take, and it has been much discussed 
lately. Without properly registered protocol information, we 
do not know the extent to which all the planned outcomes are 
reported or the nature and quality of the trial. 
In other words, if we focus on results registration without 
knowing what was really studied, and thus not knowing 
which results were not reported, we are in an environment of 
outcome reporting or even of publication bias.
In the preregistration era, results were published, but as 
there was no up-front (prospective) trial registration, there was 
no way of knowing the real quality of such publications. Such 
up-front (prospective) protocol registration will enable the 
validation of the completeness of results reporting, which in 
turn will save a lot of sponsors’ resources, particularly those of 
the pharmaceutical industry, and many lives. I would hesitate 
to participate, either as a trialist or as a study participant, in a 
trial that had not publicly disclosed at least 20 items. I would 
hesitate even more to prescribe or to use a drug developed 
through such a nontransparent process. However, I would 
be willing to consider prescribing and using a drug if I had a 
chance to analyse its potential risks and beneﬁ  ts. That would 
not have been possible without trial registration as we would 
continue to rely on the evidence based upon published results 
only, without knowing the scope of their accuracy
As of February 2006, we can say that we have deﬁ  ned, at a 
global level, a minimum-required protocol dataset via WHO’s 
trial registration project (http:⁄⁄www.who.int/ictrp). We shall 
now move on to registration and public disclosure of results. 
Of course, at the same time, we shall continue registering 
trials in member registries that provide at least 20 items. This 
must be done globally.
The lessons learned in building the culture of registration 
will be used to improve the quality of results reporting. Had 
we moved on to results too soon, it would have distracted us 
from pinning down the essential protocol information, which 
would have opened the window for continuing manipulation 
of results presentations. 
Furthermore, from a public health perspective, it is my 
hope that we shall revisit and further develop the minimal 
protocol dataset once we have been through the exercise of 
deﬁ  ning the registration of the results. This is why the Ottawa 
Group is continuing a dialogue beyond the minimal dataset.
I have no illusions that all data for all trials will be 
registered, right now, but we have made a good start in 
requesting a minimal 20-item dataset. I agree with Rockhold 
and Krall that we shall have to see how many of these 20 will 
be kept secret. 
Discovery and development in medicine is, indeed, a very 
important activity for society, and the pharmaceutical industry 
plays an important role. With regard to the social contract 
between industry and society, let me point out that social 
contracts are based upon mutual respect and conﬁ  dence, 
and they are open to revisions. Trial registration—as a tool 
of transparency, knowledge sharing, and accountability—will 
help restore the conﬁ  dence of society in the pharmaceutical 
industry, which is currently very fragile, and thus enable the 
(re-)establishment of a (new) social contract between these 
two parties.
I have looked again at the continually growing list of 
endorsements of the Ottawa Statement (OS) Part 1 [4] 
(available at http:⁄⁄ottawagroup/ohri/ca), and there is still 
no industry endorsement. Neither Rockhold nor Krall has 
signed the OS1, not even after their letter. Since they have 
declared they are “all for registering”, I am inviting them 
both again to sign the OS1, and to comment and consider 
endorsing the OS2 on principles of implementation [4].  
Karmela Krleža-Jerić
Canadian Institutes of Health Research
Ottawa, Ontario, Canada
E-mail: kkrleza-jeric@cihr-irsc.gc.ca
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Mitochondria: More than 
Mitochondrial DNA in Cancer
Bora Baysal 
In their PLoS Medicine article, entitled “A critical reassessment 
of the role of mitochondria in tumorigenesis,” Salas et al. [1] 
reviewed reports describing identiﬁ  cation of mitochondrial 
DNA (mtDNA) mutations in several tumors. They identiﬁ  ed 
many instances where the purported mutations in tumors 
corresponded to certain populational haplotypes, suggesting 
that contamination or sample mix-up could be a better 
explanation for these mtDNA variations found in tumors. 
This manuscript has important implications for this research 
ﬁ  eld by questioning the validity of conclusions drawn in 
several high-proﬁ  le publications that laid foundations for the 
role of mtDNA in cancer. While it is essential to investigate 
the origin of mtDNA variations found in certain tumors, the 
conclusion in the abstract that “the role of mitochondria in 
tumorigenesis remains unclariﬁ  ed” is simply incorrect. 
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The causal link between mitochondrial abnormalities and 
tumorigenesis was provided by the positional cloning of the 
hereditary paraganglioma gene at chromosome band 11q23 
as the SDHD subunit gene of mitochondrial complex II 
(succinate dehydrogenase) in the year 2000 [2]. Since then, 
the role of mitochondria in cancer is further highlighted 
through identiﬁ  cation of over 100 mutations in the SDHB, 
SDHC, and SDHD subunit genes in hundreds of index cases 
and families with hereditary and sporadic paragangliomas 
and pheochromocytomas [3]. Furthermore, fumarase 
gene mutations in a distinct hereditary tumor syndrome 
characterized by multiple skin and uterine leiomyomatosis 
and renal cell cancer—hereditary leiomyomatosis renal 
cancer (HLRCC)—further strengthened the role of 
mitochondria in cancer [4]. 
Although it is clear that Salas et al. question speciﬁ  cally the 
mutations in mtDNA of tumors, they did not acknowledge 
the causal link between mitochondria and cancer provided 
by the discovery of nuclear-encoded mitochondrial gene 
mutations. This is especially important because, in their 
unfortunate title and in their conclusion, the authors seem to 
make a sweeping statement against the role of mitochondria 
in cancer. It is essential to emphasize to readers that it is the 
mtDNA, but not mitochondria, which has a questionable role 
in tumorigenesis.  
Bora Baysal 
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, United States of America
E-mail: baysalb@mwri.magee.edu
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Authors’ Reply
We gratefully acknowledge the letter by Bora Baysal [1], 
which emphasizes that there is some interesting evidence 
for the role of mitochondria in tumorigenesis mediated by 
nuclear DNA factors—an issue that was outside the scope of 
our article [2]. We, however, do not entirely agree with him 
that the title of our contribution [2] is “simply incorrect”; 
it could probably be described as somewhat imprecise or 
ambiguous. In fact, the originally submitted, more precise, 
title of our contribution was “A pitcher of cold water on 
mutational hotspots in mitochondrial DNA and the hot 
debate about the role of mitochondria in tumorigenesis.” In 
any case, the Oxford English Dictionary, for example, states that 
“reassess” is “to assess again, especially differently (derivatives: 
reassessment [noun])”; synonyms of assess would be “evaluate 
or estimate.” Certainly, the role of the mitochondria has to be 
reassessed since the role of their most essential element, the 
mitochondrial genome, remains obscure in view of dozens 
of studies on the potential association of tumorigenesis 
with mitochondrial DNA (mtDNA) that are based on 
obviously ﬂ  awed data. Since those inadvertent circumstances 
(contamination and sample mix-up) are not mitochondria-
speciﬁ  c but lab-speciﬁ  c, there would also be good reason to 
reassess other spectacular DNA ﬁ  ndings in regard to potential 
laboratory errors.
We would like to stress that mtDNA somatic mutations 
are by no means uncommon either in normal tissues or in 
tumors, but the natural pattern of these somatic mutations 
(most commonly involving the polycytosine stretches and 
other well-known hotspot mutations) is quite different 
from those that were published in the papers criticized in 
our article [2]. Consistent with the title of our article [2] 
would be the possibility that the nuclear-mediated effect 
on the mitochondrial function could perhaps be mtDNA 
haplogroup–speciﬁ  c—but certainly not in the form of 
the artefactual instabilities, as claimed in those dubious 
publications (which, however, in one case, have now been 
explicitly defended [3], but unfortunately, without carrying 
out the necessary “forensic-type” analysis looking into 
potential sample mixture of the previously analyzed samples 
[4] and without determining whether the patient received 
blood transfusion before the onset of the disease [5]). Rather, 
some complex susceptibility background for tumorigenesis 
might be anticipated—in analogy to some mtDNA diseases 
such as Leber’s hereditary optic neuropathy (LHON) [6].  
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Prioritizing Investment in Medical 
Education
Fawad Aslam
The dire need to reform medical education in South Asia 
has been well emphasized in the PLoS Medicine Editorial 
[1]. It is encouraging to note that efforts are under way to 
devise strategies to bring about this reformation. However, 
for such reforms to be effective, it is crucial that the opinions 
of medical students and young doctors are also taken 
into account. Students’ roles should be enhanced from 
those of mere consumers of medical education to those of 
contributors [2]. They are important stakeholders, and their 
active participation in policymaking will facilitate the creation 
of more robust solutions.  
The need for drastic improvement in health research 
in South Asia is well established. The need for research in 
medical education is perhaps even greater. Unfortunately, 
indigenous data pertaining to medical education in this 
region are limited. Only a small number of studies have 
attempted to explore the concerns of students and doctors 
in matters pertaining to, for example, medical decision 
making and health research [3,4]. The establishment of 
a research culture is fraught with difﬁ  culties but is not 
impossible [5]. It is my opinion that, to bring about reform, 
both a “bottom-up” and a “top-down” approach are needed. 
The former needs ample student exposure to research 
during medical school. The latter is essentially linked to 
the availability of funds. No amount of community-oriented 
training, for example, will compensate for the deﬁ  ciency 
of properly qualiﬁ  ed health professionals in rural areas. It 
is only when there is sufﬁ  cient ﬁ  nancial and professional 
security that the greater purpose of educational reform 
will stand fulﬁ  lled. It is hard to envisage how this can be 
achieved when the bulk of budgetary spending pertains to 
debt-servicing and defense expenditure. 
Alongside medical education, parallel investment should 
be sought in health education, not only because our 
physicians are not cognizant of current treatment practices 
[6], but also because our patients have a poor knowledge of 
common diseases that afﬂ  ict them [7]. The interaction of 
better-informed patients and properly qualiﬁ  ed doctors may 
signiﬁ  cantly improve community health. For impoverished 
nations, the importance of preventive medicine is manifold as 
it offers the most economical way of combating disease. There 
is some evidence to suggest that our medical students are not 
“prevention” oriented, and, thus, more emphasis must be 
placed on preventive medicine [8]. 
It is also hoped that such investment will lead to nationally 
oriented research activities and not to a mere replication of 
Western studies. The study evaluating the signiﬁ  cant protective 
effects of hand washing in children from common childhood 
diseases is one such example [9]. Another example is a 
study evaluating the effects of garlic on dyslipidemia [10]. 
Further studies of this kind may prove helpful in combating 
the cardiovascular disease epidemic in Pakistan. Garlic is 
potentially a much cheaper alternative to statins, the latter 
being unaffordable for most segments of Pakistani society. 
Similarly, medical education institutions such as Aga Khan 
University in Pakistan, which is a private-sector entity, have 
started problem-based, community-oriented teaching in 
medical schools. The outcome of these curricular changes 
remains to be seen. Indeed, there is hope for South Asia, but 
for such hope to materialize, we need selﬂ  ess individuals, 
strong institutions, and perhaps above all a more just and 
realistic distribution of the national ﬁ  nancial resources.  
Fawad Aslam
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